IP Library › Granted Patent US 12,405,274
Granted Patent B2
US 12,405,274 · App. 18/191,506 · Granted Sep 2, 2025

Methods for the detection and treatment of lung cancer

Inventors: Samir Hanash (Houston, TX); Ayumu Taguchi (Houston, TX); Ziding Feng (Houston, TX)
Assignee: Board of Regents, The University of Texas System
G01N33/57423G01N33/57484G16B5/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,405,274
App. No.
18/191,506
Granted
Sep 2, 2025
Kind
B2
Abstract

Provided are methods and related kits for detection of early stage lung cancer, and determination of risk of harboring lung cancer.

Claims (11)

1. A method comprising

(a) obtaining a biological sample from a subject;

(b) measuring levels of biomarkers in the sample, wherein the biomarkers comprise CEA, CA125, CYFRA21-1, and PRO-SFTPB;

(c) combining the measured levels into a biomarker-based risk score, wherein the biomarker-based risk score is calculated using logistic regression analysis;

(d) quantifying an increased risk for the presence of lung cancer in the subject by matching the biomarker-based risk score to a risk category of a grouping of stratified subject populations, wherein each risk category comprises a multiplier indicating increased likelihood of having lung cancer correlated to a range of composite scores as compared to use of a single threshold value;

(e) classifying the subject as lung-cancer positive based on the increased risk of having lung cancer quantified in step (d); and

(f) administering to the lung-cancer positive subject a therapeutically effective amount of a treatment for the lung cancer comprising surgery, chemotherapy, immunotherapy, radiation therapy, targeted therapy, or a combination thereof.

2. The method of claim 1 , wherein the sample comprises a biological sample selected from blood, plasma, and serum.

3. The method of claim 1 , wherein measurement of the levels of CEA, CA125, CYFRA21-1, and pro-SFTPB levels is made at substantially the same time.

4. The method of claim 1 , wherein the quantification of the increased risk for the presence of lung cancer has a sensitivity of 0.76 and 0.42 at 78% and 94% specificity, respectively.

5. The method of claim 1 , wherein the quantification of the increased risk for the presence of lung cancer is diagnosed at or before the borderline resectable stage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2023
From: HANASH, SAMIR; TAGUCHI, AYUMU; FENG, ZIDING
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 063299/0394 →
Continuity (3)
Division 16484177
Provisional Application 62456731 · Feb 9, 2017
Related Publication 20230314436A1 · Oct 5, 2023
References Cited (38)
US 20080133141A1 · Frost · 2008 [cited by applicant]
US 20130196868A1 · Lebowitz · 2013 [cited by applicant]
US 20140271453A1 · Dowell · 2014 [cited by applicant]
US 20140274772A1 · Borgia · 2014 [cited by applicant]
US 20150072890A1 · James · 2015 [cited by applicant]
US 20160060329A1 · Sin · 2016 [cited by applicant]
US 20200025766A1 · Hanash · 2020 [cited by applicant]
US 20240159753A1 · Hanash · 2024 [cited by examiner]
CN 102321760 · 2012 [cited by applicant]
WO 2007076439 · 2007 [cited by applicant]
WO 2008144034 · 2008 [cited by applicant]
WO 2011140234 · 2011 [cited by applicant]
WO 2011150974 · 2011 [cited by applicant]
WO 2016205960 · 2016 [cited by applicant]
WO 2017155570 · 2017 [cited by applicant]
WO 2018148600 · 2018 [cited by applicant]
Bach, P. et al., “Variations in Lung Cancer Risk Among Smokers”, J Natl Cancer Inst., 95(6):470-8, (2003). [cited by applicant]
Cassidy, A. et al., “The LLP Risk Model: An Individual Risk Prediction Model for Lung Cancer”, Br J Cancer, 98 (2):270-6, (2008). [cited by applicant]
EP Patent Application No. 18752036.6; Third Party Observations under Article 115 EPC, dated Dec. 11, 2019; 3 pages. [cited by applicant]
Fahrmann, J. et al., “Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment”, J Clin Oncol., 40(8):876-83, (2022). [cited by applicant]
Fernandez-Cuesta, L. et al., “Identification of Circulating Tumor DNA for the Early Detection of Small-Cell Lung Cancer”, EBioMedicine, 10:117-23, (2016). [cited by applicant]
Hoggart, C. et al., “A Risk Model for Lung Cancer Incidence”, Cancer Prev Res (Phila)., 5(6):834-46, (2012). [cited by applicant]
International Application No. PCT/US2018/017704; International Preliminary Report on Patentability, date of issuance Aug. 13, 2018; 34 pages. [cited by applicant]
International Application No. PCT/US2018/017704; International Search Report and Written Opinion of the International Searching Authority, date of mailing Apr. 27, 2018; 37 pages. [cited by applicant]
Jett, J. et al., “Audit of the Autoantibody Test, EarlyCDT-Lung, in 1600 Patients: An Evolution of It's Performance in Routine Clinical Practice”, Lung Cancer, 83(1):51-5, (2014). [cited by applicant]
Johansson, M. et al., “Comprehensive Evaluation of Promising Biomarkers for Lung Cancer Risk Prediction”, Cancer Res., 76(14):Abstract 2259, (2016). [cited by applicant]
Johansson, M., “Can Biomarkers be Used to Improve Risk Prediction Models on Lung Cancer?” IARC/WHO presentation, 38 pages, (2016). [cited by applicant]
Johansson, M., “Can Biomarkers be Used to Improve Risk Prediction Models on Lung Cancer?”, Cancer Epidemiology, Biomarkers & Prevention, Abstract IA19, 4 pages, (2016). [cited by applicant]
Sequist, L. et al., “A New Era of Protein-Based Assays for Cancer Early Detection”, J Thorac Oncol., 16(2):191-3, (2021). [cited by applicant]
Sin, D. et al., “Pro-Surfactant Protein B as a Biomarker for Lung Cancer Prediction”, J Clin Oncol., 31(36):4536-43, (2013). [cited by applicant]
Sozzi, G. et al., “Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study”, J Clin Oncol., 32(8):768-73, (Mar. 10, 2014). [cited by applicant]
Spitz, M. et al., “An Expanded Risk Prediction Model for Lung Cancer”, Cancer Prev Res (Phila)., 1(4):250-4, (2008). [cited by applicant]
U.S. Appl. No. 16/484,177; Non-Final Office Action, dated Dec. 22, 2022; 22 pages. [cited by applicant]
Wikoff, W. et al., “Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B”, J Clin Oncol., 33(33):3880-6, (2015). [cited by applicant]
U.S. Appl. No. 16/484,177; Final Office Action, dated Aug. 10, 2023; 15 pages. [cited by applicant]
Cedrés, S. et al., “Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)”, Clin Lung Cancer, 12(3):172-9, (2011). [cited by applicant]
Molina, R. et al., “Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological … [cited by applicant]
U.S. Appl. No. 16/484,177; Final Office Action, dated Nov. 4, 2024; 12 pages. [cited by applicant]